| Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED |
2021-02-17 |
| Thermo Fisher–Sidis: cell sorting technology, 202102 acquisition cell sorting assets incl Bigfoot Spectral Cell Sorter + 40 employees from Propel Labs |
2021-02-17 |
| WuXi PharmaTech–Quanterix: biomarker services, 202102– collab establishment Simoa Joint Lab at WuXI AppTec’s Shanghai facility using HD-X Analyzers |
2021-02-12 |
| Ensoma–1AB Media: public relations, 202102 service existent by 1AB Media |
2021-02-11 |
| Ensoma–5AM Ventures: investment, 202102 financing round Series A totalling $70m incl existing co-founder + seed + lead investor 5AM Ventures |
2021-02-11 |
| Ensoma–F-Prime: investment, 202102 financing round Series A totalling $70m incl co-investor F-Prime Capital |
2021-02-11 |
| Ensoma–SEVERAL: investment, 202102 financing round Series A $70m led by existing co-founder + seed investor 5AM Ventures |
2021-02-11 |
| Ensoma–Takeda: investment, 202102 financing round Series A totalling $70m incl $10m from co-investor Takeda Ventures in connection with collab |
2021-02-11 |
| NexImmune–PNC Financial Services: public relations, 202102 service existent IR by Solebury Trout |
2021-02-11 |
| NexImmune–Sam Brown: public relations, 202102 service existent by Sam Brown Inc |
2021-02-11 |
| NexImmune–SEVERAL: investment, 202102 IPO $110m+$16.5m with 6.47m+971k shares common stock at $17/share at Nasdaq Global Market |
2021-02-11 |
| Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact |
2021-02-11 |
| BigHat Biosciences–8VC: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor 8VC |
2021-02-10 |
| BigHat Biosciences–AME Cloud Ventures: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor AME Cloud Ventures |
2021-02-10 |
| BigHat Biosciences–Andreessen Horowitz: investment, 202102 financing round Series A totalling $19m incl lead investor a16z |
2021-02-10 |
| BigHat Biosciences–Innovation Endeavors: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor Innovation Endeavors |
2021-02-10 |
| BigHat Biosciences–SEVERAL: investment, 202102 financing round Series A $19m led by Andreessen Horowitz |
2021-02-10 |
| Pacific Biosciences–SoftBank: credit, 202102–202802 senior convertible notes $900m due 2028 with 1.5% interest/year |
2021-02-10 |
| SpyBiotech–Alphabet: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor GV |
2021-02-10 |
| SpyBiotech–Braavos Investment Advisors: investment, 202102 financing round Series A totalling $32.5m incl new + lead investor Braavos |
2021-02-10 |
| SpyBiotech–Oxford Investment Consultants: investment, 202102 financing round Series A totalling $32.5m incl new + co-investor OIC |
2021-02-10 |
| SpyBiotech–SEVERAL: investment, 202102 financing round Series A $32.5m led by new investor Braavos Investment Advisers |
2021-02-10 |
| SpyBiotech–United Kigdom (govt): investment, 202102 financing round Series A totalling $32.5m incl Future Fund converting prior convertible loan |
2021-02-10 |
| SpyBiotech–Univ Oxford: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor Oxford Sciences Innovation |
2021-02-10 |
| Adagene–6 Degrees Communications: public relations, 202102 service existent media relations by 6 Degrees |
2021-02-09 |
| Adagene–SEVERAL: investment, 202102 US IPO $140m+$21m with 7.4mm+1.1m ADSs at $19/ADS at Nasdaq Global Market |
2021-02-09 |
| Vor Biopharma–SEVERAL: investment, 202102 IPO $176.9m+$25.5m with 9.8m+1.5m common shares at $18/share |
2021-02-05 |
| PepGen–Verge Scientific Communications: public relations, 202102 service existent by Verge |
2021-02-04 |
| Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson |
2021-02-03 |
| Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
| GW Pharmaceuticals–Jazz Pharmaceuticals: investment, 202102– acquisition $7.2b at $220/ADS with $200 in cash + $20 in ordinary shares ANNOUNCED |
2021-02-03 |
| Landos Biopharma–PNC Financial Services: public relations, 202011 service existent PR + IR by Solebury Trout |
2021-02-03 |
| Landos Biopharma–SEVERAL: investment, 202102 IPO $100m+$15m with 6.25m+937.5k shares common stock at $16/share at Nasdaq Global Select Market |
2021-02-03 |
| Quanterix–SEVERAL: investment, 202102 public offering $250m+$37.5m with 3.6m+535k shares common stock at $70/share with full overallotment |
2021-02-03 |
| Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy |
2021-02-02 |
| Cellino–8VC: investment, 202102 seed financing round $16m incl co-investor 8VC |
2021-02-01 |
| Cellino–Humboldt Fund: investment, 202102 seed financing round $16m incl co-investor Humboldt Fund |
2021-02-01 |
| Cellino–Khosla Ventures: investment, 202102 seed financing round $16m incl co-lead investor Khosla Ventures |
2021-02-01 |
| Cellino–MIT: investment, 202102 seed financing round $16m incl co-lead investor The Engine |
2021-02-01 |
| Cellino–SEVERAL: investment, 202102 seed financing round $16m from The Engine + Khosla Ventures + Humboldt Fund + 8VC |
2021-02-01 |
| Exelixis–Adagene: antibody technology, 202102– collab + license $11m upfront + milestones + royalties using SAFEbody techn to mask MAbs for ADCs et al |
2021-02-01 |
| Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD |
2021-01-28 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| BiondVax–SEVERAL: investment, 202101– Pulbic Offering $12m+$1.8m with 2.4m+365k ADSs at $4.95/ADS |
2021-01-28 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| Lauxera Capital–SEVERAL: investment, 2020–2021 launch of €100m fund incl investors Bpifrance + Covéa + Téthys + CNP et al |
2021-01-27 |
| Encodia–Alexandria Real Estate: investment, 202101 financing round Series C totalling $75m incl new + co-investor Alexandria Venture Investments |
2021-01-26 |
| Encodia–Alphabet: investment, 202101 financing round Series C totalling $75m incl new + co-investor GV |
2021-01-26 |
| Encodia–ARCH Venture: investment, 202101 financing round Series C totalling $75m incl existing + co-investor ARCH Venture Partners |
2021-01-26 |
| Encodia–Biomatics Capital: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Biomatics Capital |
2021-01-26 |
| Encodia–Decheng Capital: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Decheng Capital |
2021-01-26 |
| Encodia–Deerfield: investment, 202101 financing round Series C totalling $75m incl co-lead investor Deerfield Management |
2021-01-26 |
| Encodia–Nan Fung: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Nan Fung Life Sciences |
2021-01-26 |
| Encodia–Northpond Ventures: investment, 202101 financing round Series C totalling $75m incl co-lead investor Northpond Ventures |
2021-01-26 |
| Encodia–SEVERAL: investment, 202101 financing round Series C $75m led by Northpond Ventures + Deerfield Management |
2021-01-26 |
| Encodia–Tao Capital Partners: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Tao Capital Partners |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| Mobilion–Protein Metrics: mass spectrometry software, 202101– collab integration of Byos software suit with Mobilion HRIM MS system |
2021-01-26 |
| AgeX Therapeutics–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital |
2021-01-25 |
| Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital |
2021-01-25 |
| CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
| Elevian–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| FoxBio–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Lift BioSciences–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Maia Biotechnology–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Oisin Biotechnologies–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| TScan Therapeutics–6 Dimensions Capital: investment, 202101 financing round Series C totalling $100m incl existing investor 6 Dimensions Capital |
2021-01-25 |
| TScan Therapeutics–Alphabet: investment, 202101 financing round Series C totalling $100m incl existing investor GV |
2021-01-25 |
| TScan Therapeutics–Argot Partners: public relations, 202101 service existent media relations + IR by Argot Partners |
2021-01-25 |
| TScan Therapeutics–Bessemer Venture: investment, 202101 financing round Series C totalling $100m incl existing investor Bessemer Venture Partners |
2021-01-25 |
| TScan Therapeutics–BlackRock: investment, 202101 financing round Series C totalling $100m incl new investor funds + accounts managed by Black Rock |
2021-01-25 |
| TScan Therapeutics–Longwood Fund: investment, 202101 financing round Series C totalling $100m incl founding + existing investor Longwood Fund |
2021-01-25 |
| TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund |
2021-01-25 |
| TScan Therapeutics–Pitango: investment, 202101 financing round Series C totalling $100m incl existing investor Pitango HealthTech |
2021-01-25 |
| TScan Therapeutics–RA Capital: investment, 202101 financing round Series C totalling $100m incl new investor RA Capital Management |
2021-01-25 |
| TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital |
2021-01-25 |
| Turn.Bio–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Servier–MiNA Therapeutics: saRNA therapeutics, 202101– collab research + license option for saRNA therapeutics for neurological diaseses |
2021-01-21 |
| Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq |
2021-01-20 |
| Neuvogen–10K Partners: public relations, 202101 service existent by 10K Partners |
2021-01-20 |
| ConserV Bioscience–Optimum Strategic Communications: public relations, 202101 service existent by Optimum |
2021-01-19 |
| ConserV Bioscience–United States (govt): coronavirus vaccine, 202101– collab developm broad spectrum coronvirus vaccine using NLP technology from LLNL |
2021-01-19 |
| CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion |
2021-01-19 |
| Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share |
2021-01-19 |
| Mesa Biotech–Thermo Fisher: investment, 202101– acquisition $450m cash upfront + $100m cash milestones of Mesa Biotech Inc by Thermo Fisher |
2021-01-19 |
| Slate Bio–Epidarex Capital: investment, 202101 seed financing round totalling $1.75m incl lead investor Epidarex Capital |
2021-01-19 |
| Slate Bio–SEVERAL: investment, 202101 seed financing round $1.75m led by Epidarex Capital |
2021-01-19 |
| Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher |
2021-01-15 |
| NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital |
2021-01-14 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| AltPep–Alexandria Real Estate: investment, 202101 fianncing round Series A totalling $23.15m inc significant participation by Alexanria VI |
2021-01-12 |
| AltPep–Matrix Capital Management: investment, 202101 fianncing round Series A totalling $23.15m inc lead investor Matrix Capital Mgt |
2021-01-12 |
| AltPep–SEVERAL: investment, 202101 fianncing round Series A $23.15m led by Matrix Capital Mgt with significant participation by Alexandria VI |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Fighting Customers 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-fighting-customers.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
